nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRNB2—prostate gland—prostate cancer	0.00596	0.175	CbGeAlD
Varenicline—CHRNA3—prostate gland—prostate cancer	0.00578	0.17	CbGeAlD
Varenicline—CHRNB2—urethra—prostate cancer	0.00399	0.117	CbGeAlD
Varenicline—CHRNA6—Nicotine Activity on Dopaminergic Neurons—TH—prostate cancer	0.00356	0.031	CbGpPWpGaD
Varenicline—CHRNB2—Nicotine Activity on Dopaminergic Neurons—TH—prostate cancer	0.00314	0.0273	CbGpPWpGaD
Varenicline—CHRNB2—bone marrow—prostate cancer	0.00307	0.0903	CbGeAlD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—NKX3-1—prostate cancer	0.00268	0.0234	CbGpPWpGaD
Varenicline—CHRNB2—testis—prostate cancer	0.00263	0.0772	CbGeAlD
Varenicline—CHRNB2—Circadian rythm related genes—ZFHX3—prostate cancer	0.00258	0.0224	CbGpPWpGaD
Varenicline—CHRNA7—renal system—prostate cancer	0.00257	0.0756	CbGeAlD
Varenicline—CHRNA3—testis—prostate cancer	0.00255	0.0748	CbGeAlD
Varenicline—CHRNA3—Nicotine Activity on Dopaminergic Neurons—TH—prostate cancer	0.00226	0.0197	CbGpPWpGaD
Varenicline—CHRFAM7A—testis—prostate cancer	0.00206	0.0605	CbGeAlD
Varenicline—CHRNB2—lymph node—prostate cancer	0.0019	0.0559	CbGeAlD
Varenicline—CHRNA3—lymph node—prostate cancer	0.00185	0.0543	CbGeAlD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—NKX3-1—prostate cancer	0.00183	0.016	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—ASCL1—prostate cancer	0.00181	0.0158	CbGpPWpGaD
Varenicline—CHRNA4—Nicotine Activity on Dopaminergic Neurons—TH—prostate cancer	0.00175	0.0152	CbGpPWpGaD
Varenicline—CHRNA7—testis—prostate cancer	0.00166	0.0489	CbGeAlD
Varenicline—CHRNB2—Circadian rythm related genes—NAGLU—prostate cancer	0.00156	0.0136	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RRAS—prostate cancer	0.00156	0.0135	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—NKX3-1—prostate cancer	0.0015	0.013	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—KCNN3—prostate cancer	0.00145	0.0126	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—ID3—prostate cancer	0.00141	0.0123	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RRAS—prostate cancer	0.00137	0.0119	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—KCNN3—prostate cancer	0.00128	0.0111	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—ASCL1—prostate cancer	0.00124	0.0108	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.00118	0.0103	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—RRAS—prostate cancer	0.00117	0.0102	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HSP90B1—prostate cancer	0.00117	0.0102	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.00107	0.00931	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.00104	0.00904	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—RRAS—prostate cancer	0.00103	0.00896	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—ASCL1—prostate cancer	0.00101	0.00879	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RRAS—prostate cancer	0.000987	0.00859	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000942	0.0082	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RRAS—prostate cancer	0.000936	0.00815	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—KCNN3—prostate cancer	0.00092	0.008	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000913	0.00794	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—RRAS—prostate cancer	0.000897	0.0078	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000887	0.00772	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—KCNN3—prostate cancer	0.000873	0.0076	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—HNF1B—prostate cancer	0.000872	0.00759	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000846	0.00736	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—GNG5—prostate cancer	0.000805	0.007	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000803	0.00699	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HSP90B1—prostate cancer	0.000798	0.00695	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—RRAS—prostate cancer	0.000789	0.00687	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000781	0.00679	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PRKDC—prostate cancer	0.000778	0.00677	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RRAS—prostate cancer	0.000763	0.00664	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.000748	0.00651	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000745	0.00648	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—AHR—prostate cancer	0.000742	0.00645	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—RRAS—prostate cancer	0.000742	0.00645	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—PRKACB—prostate cancer	0.000737	0.00641	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—ACHE—prostate cancer	0.000717	0.00624	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—KCNN3—prostate cancer	0.000712	0.00619	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.00071	0.00617	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—GNG5—prostate cancer	0.000708	0.00616	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—RRAS—prostate cancer	0.000704	0.00612	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000686	0.00597	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL1RN—prostate cancer	0.000686	0.00596	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—PLCB2—prostate cancer	0.000679	0.00591	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000679	0.0059	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HSP90B1—prostate cancer	0.000651	0.00566	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—SLC22A1—prostate cancer	0.000648	0.00564	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000644	0.0056	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.000635	0.00553	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—ACHE—prostate cancer	0.000631	0.00549	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TH—prostate cancer	0.000631	0.00549	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—GNG5—prostate cancer	0.000617	0.00536	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000604	0.00525	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—PLCB2—prostate cancer	0.000598	0.0052	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.000594	0.00517	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TOP2A—prostate cancer	0.000589	0.00513	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000579	0.00503	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.000579	0.00503	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—RRAS—prostate cancer	0.000574	0.00499	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—SLC22A1—prostate cancer	0.000571	0.00496	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—RRAS—prostate cancer	0.000568	0.00494	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NCOA2—prostate cancer	0.000567	0.00494	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.000566	0.00492	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000562	0.00489	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—AR—prostate cancer	0.000561	0.00488	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EZH2—prostate cancer	0.00056	0.00487	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—ACHE—prostate cancer	0.00055	0.00478	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000549	0.00478	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—GNG5—prostate cancer	0.000543	0.00472	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—RRAS—prostate cancer	0.000539	0.00469	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000536	0.00467	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000534	0.00464	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—PRKACB—prostate cancer	0.000526	0.00457	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000525	0.00457	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TH—prostate cancer	0.000515	0.00448	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—GNG5—prostate cancer	0.00051	0.00444	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000509	0.00443	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—PRKACB—prostate cancer	0.000503	0.00438	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—COMT—prostate cancer	0.0005	0.00435	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000491	0.00427	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EGR1—prostate cancer	0.000485	0.00422	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—GNG5—prostate cancer	0.000484	0.00421	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—ACHE—prostate cancer	0.000484	0.00421	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NGFR—prostate cancer	0.000482	0.0042	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL1RN—prostate cancer	0.000468	0.00408	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—PRKACB—prostate cancer	0.000463	0.00403	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—ACHE—prostate cancer	0.000455	0.00396	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000454	0.00395	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000448	0.00389	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—COMT—prostate cancer	0.00044	0.00383	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—RRAS—prostate cancer	0.00044	0.00383	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000435	0.00378	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000435	0.00378	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.000434	0.00378	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—ACHE—prostate cancer	0.000431	0.00375	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TH—prostate cancer	0.000431	0.00375	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—PLCB2—prostate cancer	0.000431	0.00375	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—SIRT1—prostate cancer	0.000418	0.00364	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000415	0.00361	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000414	0.0036	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000413	0.00359	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—SLC22A1—prostate cancer	0.000411	0.00358	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—PRKACB—prostate cancer	0.00041	0.00357	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—PLCB2—prostate cancer	0.000409	0.00356	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.000406	0.00353	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TYMS—prostate cancer	0.000405	0.00353	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—GNG5—prostate cancer	0.000395	0.00343	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—GNG5—prostate cancer	0.000391	0.0034	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—SLC22A1—prostate cancer	0.00039	0.00339	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.000387	0.00336	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—AR—prostate cancer	0.000384	0.00334	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—COMT—prostate cancer	0.000383	0.00333	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL1RN—prostate cancer	0.000382	0.00332	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—GNG5—prostate cancer	0.000371	0.00323	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000355	0.00309	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.000354	0.00308	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—ACHE—prostate cancer	0.000352	0.00306	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TH—prostate cancer	0.000351	0.00306	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—ACHE—prostate cancer	0.000348	0.00303	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PPARA—prostate cancer	0.000347	0.00302	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.000338	0.00294	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—COMT—prostate cancer	0.000337	0.00293	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000336	0.00293	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000335	0.00292	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—PRKACB—prostate cancer	0.000333	0.0029	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—PLCB2—prostate cancer	0.000333	0.0029	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.000331	0.00288	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—ACHE—prostate cancer	0.000331	0.00288	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—LEP—prostate cancer	0.00033	0.00287	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—SLC22A1—prostate cancer	0.000318	0.00277	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—COMT—prostate cancer	0.000317	0.00275	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—PRKACB—prostate cancer	0.000316	0.00275	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.000315	0.00274	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000313	0.00272	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—AR—prostate cancer	0.000313	0.00272	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.00031	0.0027	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—GNG5—prostate cancer	0.000302	0.00263	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—COMT—prostate cancer	0.0003	0.00261	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—GSK3B—prostate cancer	0.000285	0.00248	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000283	0.00246	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000273	0.00238	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—ACHE—prostate cancer	0.000269	0.00234	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000268	0.00233	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000267	0.00232	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—SERPINE1—prostate cancer	0.000259	0.00225	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—PRKACB—prostate cancer	0.000258	0.00224	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000257	0.00223	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000253	0.0022	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.000248	0.00215	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—COMT—prostate cancer	0.000245	0.00213	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—COMT—prostate cancer	0.000243	0.00211	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000235	0.00205	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.000231	0.00201	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.00023	0.002	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—COMT—prostate cancer	0.00023	0.002	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—EP300—prostate cancer	0.00023	0.002	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000225	0.00196	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000218	0.0019	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000214	0.00186	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—MDM2—prostate cancer	0.000205	0.00178	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PTEN—prostate cancer	0.000197	0.00171	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.000188	0.00164	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EP300—prostate cancer	0.000188	0.00163	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—COMT—prostate cancer	0.000188	0.00163	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000183	0.00159	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—MDM2—prostate cancer	0.00018	0.00157	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000175	0.00153	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000174	0.00152	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000169	0.00147	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.000169	0.00147	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000161	0.0014	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—EP300—prostate cancer	0.000157	0.00137	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6—prostate cancer	0.000151	0.00131	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000149	0.0013	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000149	0.0013	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000143	0.00124	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.000138	0.0012	CbGpPWpGaD
Varenicline—Nausea—Estradiol—prostate cancer	0.000137	0.000161	CcSEcCtD
Varenicline—Vomiting—Mitoxantrone—prostate cancer	0.000137	0.000161	CcSEcCtD
Varenicline—Sinusitis—Doxorubicin—prostate cancer	0.000137	0.000161	CcSEcCtD
Varenicline—Convulsion—Prednisone—prostate cancer	0.000136	0.00016	CcSEcCtD
Varenicline—Visual impairment—Epirubicin—prostate cancer	0.000136	0.00016	CcSEcCtD
Varenicline—Hypertension—Prednisone—prostate cancer	0.000136	0.00016	CcSEcCtD
Varenicline—Rash—Mitoxantrone—prostate cancer	0.000136	0.00016	CcSEcCtD
Varenicline—Dermatitis—Mitoxantrone—prostate cancer	0.000136	0.00016	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000136	0.000159	CcSEcCtD
Varenicline—Headache—Mitoxantrone—prostate cancer	0.000135	0.000159	CcSEcCtD
Varenicline—Hypotension—Capecitabine—prostate cancer	0.000135	0.000158	CcSEcCtD
Varenicline—Insomnia—Docetaxel—prostate cancer	0.000135	0.000158	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—TP53—prostate cancer	0.000134	0.00117	CbGpPWpGaD
Varenicline—Myalgia—Prednisone—prostate cancer	0.000134	0.000157	CcSEcCtD
Varenicline—Arthralgia—Prednisone—prostate cancer	0.000134	0.000157	CcSEcCtD
Varenicline—Erythema multiforme—Epirubicin—prostate cancer	0.000134	0.000157	CcSEcCtD
Varenicline—Anxiety—Prednisone—prostate cancer	0.000134	0.000157	CcSEcCtD
Varenicline—Bradycardia—Doxorubicin—prostate cancer	0.000133	0.000157	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000133	0.000156	CcSEcCtD
Varenicline—Dyspnoea—Docetaxel—prostate cancer	0.000133	0.000156	CcSEcCtD
Varenicline—Somnolence—Docetaxel—prostate cancer	0.000132	0.000156	CcSEcCtD
Varenicline—Discomfort—Prednisone—prostate cancer	0.000132	0.000156	CcSEcCtD
Varenicline—Eye disorder—Epirubicin—prostate cancer	0.000132	0.000155	CcSEcCtD
Varenicline—Hypersensitivity—Etoposide—prostate cancer	0.000132	0.000155	CcSEcCtD
Varenicline—Tinnitus—Epirubicin—prostate cancer	0.000132	0.000155	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000131	0.000154	CcSEcCtD
Varenicline—Cardiac disorder—Epirubicin—prostate cancer	0.000131	0.000154	CcSEcCtD
Varenicline—Dyspepsia—Docetaxel—prostate cancer	0.000131	0.000154	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000131	0.00114	CbGpPWpGaD
Varenicline—Insomnia—Capecitabine—prostate cancer	0.00013	0.000153	CcSEcCtD
Varenicline—Hypoaesthesia—Doxorubicin—prostate cancer	0.00013	0.000153	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—MDM2—prostate cancer	0.00013	0.00113	CbGpPWpGaD
Varenicline—Decreased appetite—Docetaxel—prostate cancer	0.000129	0.000152	CcSEcCtD
Varenicline—Urinary tract disorder—Doxorubicin—prostate cancer	0.000129	0.000152	CcSEcCtD
Varenicline—Oedema peripheral—Doxorubicin—prostate cancer	0.000129	0.000151	CcSEcCtD
Varenicline—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000129	0.000151	CcSEcCtD
Varenicline—Asthenia—Etoposide—prostate cancer	0.000129	0.000151	CcSEcCtD
Varenicline—Connective tissue disorder—Doxorubicin—prostate cancer	0.000129	0.000151	CcSEcCtD
Varenicline—Dyspnoea—Capecitabine—prostate cancer	0.000129	0.000151	CcSEcCtD
Varenicline—Oedema—Prednisone—prostate cancer	0.000128	0.000151	CcSEcCtD
Varenicline—Fatigue—Docetaxel—prostate cancer	0.000128	0.000151	CcSEcCtD
Varenicline—Angiopathy—Epirubicin—prostate cancer	0.000128	0.000151	CcSEcCtD
Varenicline—Urethral disorder—Doxorubicin—prostate cancer	0.000128	0.000151	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—EP300—prostate cancer	0.000128	0.00111	CbGpPWpGaD
Varenicline—Nausea—Mitoxantrone—prostate cancer	0.000128	0.00015	CcSEcCtD
Varenicline—Immune system disorder—Epirubicin—prostate cancer	0.000128	0.00015	CcSEcCtD
Varenicline—Infection—Prednisone—prostate cancer	0.000128	0.00015	CcSEcCtD
Varenicline—Mediastinal disorder—Epirubicin—prostate cancer	0.000127	0.00015	CcSEcCtD
Varenicline—Constipation—Docetaxel—prostate cancer	0.000127	0.00015	CcSEcCtD
Varenicline—Pain—Docetaxel—prostate cancer	0.000127	0.00015	CcSEcCtD
Varenicline—Dyspepsia—Capecitabine—prostate cancer	0.000127	0.000149	CcSEcCtD
Varenicline—Chills—Epirubicin—prostate cancer	0.000127	0.000149	CcSEcCtD
Varenicline—Pruritus—Etoposide—prostate cancer	0.000127	0.000149	CcSEcCtD
Varenicline—Shock—Prednisone—prostate cancer	0.000126	0.000149	CcSEcCtD
Varenicline—Arrhythmia—Epirubicin—prostate cancer	0.000126	0.000148	CcSEcCtD
Varenicline—Visual impairment—Doxorubicin—prostate cancer	0.000126	0.000148	CcSEcCtD
Varenicline—Nervous system disorder—Prednisone—prostate cancer	0.000126	0.000148	CcSEcCtD
Varenicline—Tachycardia—Prednisone—prostate cancer	0.000125	0.000147	CcSEcCtD
Varenicline—Decreased appetite—Capecitabine—prostate cancer	0.000125	0.000147	CcSEcCtD
Varenicline—Skin disorder—Prednisone—prostate cancer	0.000125	0.000147	CcSEcCtD
Varenicline—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000125	0.000146	CcSEcCtD
Varenicline—Fatigue—Capecitabine—prostate cancer	0.000124	0.000146	CcSEcCtD
Varenicline—Hyperhidrosis—Prednisone—prostate cancer	0.000124	0.000146	CcSEcCtD
Varenicline—Mental disorder—Epirubicin—prostate cancer	0.000124	0.000146	CcSEcCtD
Varenicline—Erythema multiforme—Doxorubicin—prostate cancer	0.000124	0.000145	CcSEcCtD
Varenicline—Constipation—Capecitabine—prostate cancer	0.000123	0.000145	CcSEcCtD
Varenicline—Pain—Capecitabine—prostate cancer	0.000123	0.000145	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—MDM2—prostate cancer	0.000123	0.00107	CbGpPWpGaD
Varenicline—Erythema—Epirubicin—prostate cancer	0.000123	0.000145	CcSEcCtD
Varenicline—Malnutrition—Epirubicin—prostate cancer	0.000123	0.000145	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—IL6—prostate cancer	0.000123	0.00107	CbGpPWpGaD
Varenicline—Feeling abnormal—Docetaxel—prostate cancer	0.000123	0.000144	CcSEcCtD
Varenicline—Diarrhoea—Etoposide—prostate cancer	0.000123	0.000144	CcSEcCtD
Varenicline—Anorexia—Prednisone—prostate cancer	0.000122	0.000144	CcSEcCtD
Varenicline—Eye disorder—Doxorubicin—prostate cancer	0.000122	0.000144	CcSEcCtD
Varenicline—Tinnitus—Doxorubicin—prostate cancer	0.000122	0.000143	CcSEcCtD
Varenicline—Gastrointestinal pain—Docetaxel—prostate cancer	0.000122	0.000143	CcSEcCtD
Varenicline—Cardiac disorder—Doxorubicin—prostate cancer	0.000121	0.000143	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000121	0.00106	CbGpPWpGaD
Varenicline—Flatulence—Epirubicin—prostate cancer	0.000121	0.000143	CcSEcCtD
Varenicline—Dysgeusia—Epirubicin—prostate cancer	0.000121	0.000142	CcSEcCtD
Varenicline—Back pain—Epirubicin—prostate cancer	0.000119	0.00014	CcSEcCtD
Varenicline—Feeling abnormal—Capecitabine—prostate cancer	0.000119	0.00014	CcSEcCtD
Varenicline—Angiopathy—Doxorubicin—prostate cancer	0.000119	0.00014	CcSEcCtD
Varenicline—Dizziness—Etoposide—prostate cancer	0.000119	0.000139	CcSEcCtD
Varenicline—Muscle spasms—Epirubicin—prostate cancer	0.000118	0.000139	CcSEcCtD
Varenicline—Immune system disorder—Doxorubicin—prostate cancer	0.000118	0.000139	CcSEcCtD
Varenicline—Gastrointestinal pain—Capecitabine—prostate cancer	0.000118	0.000139	CcSEcCtD
Varenicline—Mediastinal disorder—Doxorubicin—prostate cancer	0.000118	0.000139	CcSEcCtD
Varenicline—Abdominal pain—Docetaxel—prostate cancer	0.000118	0.000138	CcSEcCtD
Varenicline—Body temperature increased—Docetaxel—prostate cancer	0.000118	0.000138	CcSEcCtD
Varenicline—Chills—Doxorubicin—prostate cancer	0.000117	0.000138	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000117	0.000138	CcSEcCtD
Varenicline—Arrhythmia—Doxorubicin—prostate cancer	0.000117	0.000137	CcSEcCtD
Varenicline—Insomnia—Prednisone—prostate cancer	0.000116	0.000137	CcSEcCtD
Varenicline—Vision blurred—Epirubicin—prostate cancer	0.000116	0.000136	CcSEcCtD
Varenicline—Mental disorder—Doxorubicin—prostate cancer	0.000115	0.000135	CcSEcCtD
Varenicline—Urticaria—Capecitabine—prostate cancer	0.000115	0.000135	CcSEcCtD
Varenicline—Ill-defined disorder—Epirubicin—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Abdominal pain—Capecitabine—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Body temperature increased—Capecitabine—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Vomiting—Etoposide—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Erythema—Doxorubicin—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Malnutrition—Doxorubicin—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Anaemia—Epirubicin—prostate cancer	0.000114	0.000134	CcSEcCtD
Varenicline—Agitation—Epirubicin—prostate cancer	0.000113	0.000133	CcSEcCtD
Varenicline—Dyspepsia—Prednisone—prostate cancer	0.000113	0.000133	CcSEcCtD
Varenicline—Rash—Etoposide—prostate cancer	0.000113	0.000133	CcSEcCtD
Varenicline—Dermatitis—Etoposide—prostate cancer	0.000113	0.000133	CcSEcCtD
Varenicline—Headache—Etoposide—prostate cancer	0.000112	0.000132	CcSEcCtD
Varenicline—Flatulence—Doxorubicin—prostate cancer	0.000112	0.000132	CcSEcCtD
Varenicline—Decreased appetite—Prednisone—prostate cancer	0.000112	0.000131	CcSEcCtD
Varenicline—Dysgeusia—Doxorubicin—prostate cancer	0.000112	0.000131	CcSEcCtD
Varenicline—Malaise—Epirubicin—prostate cancer	0.000111	0.00013	CcSEcCtD
Varenicline—Fatigue—Prednisone—prostate cancer	0.000111	0.00013	CcSEcCtD
Varenicline—Vertigo—Epirubicin—prostate cancer	0.000111	0.00013	CcSEcCtD
Varenicline—Syncope—Epirubicin—prostate cancer	0.00011	0.00013	CcSEcCtD
Varenicline—Back pain—Doxorubicin—prostate cancer	0.00011	0.000129	CcSEcCtD
Varenicline—Constipation—Prednisone—prostate cancer	0.00011	0.000129	CcSEcCtD
Varenicline—Hypersensitivity—Docetaxel—prostate cancer	0.00011	0.000129	CcSEcCtD
Varenicline—Muscle spasms—Doxorubicin—prostate cancer	0.00011	0.000129	CcSEcCtD
Varenicline—Palpitations—Epirubicin—prostate cancer	0.000109	0.000128	CcSEcCtD
Varenicline—Loss of consciousness—Epirubicin—prostate cancer	0.000108	0.000127	CcSEcCtD
Varenicline—Cough—Epirubicin—prostate cancer	0.000107	0.000126	CcSEcCtD
Varenicline—Vision blurred—Doxorubicin—prostate cancer	0.000107	0.000126	CcSEcCtD
Varenicline—Asthenia—Docetaxel—prostate cancer	0.000107	0.000126	CcSEcCtD
Varenicline—Convulsion—Epirubicin—prostate cancer	0.000107	0.000125	CcSEcCtD
Varenicline—Nausea—Etoposide—prostate cancer	0.000106	0.000125	CcSEcCtD
Varenicline—Hypertension—Epirubicin—prostate cancer	0.000106	0.000125	CcSEcCtD
Varenicline—Hypersensitivity—Capecitabine—prostate cancer	0.000106	0.000125	CcSEcCtD
Varenicline—Feeling abnormal—Prednisone—prostate cancer	0.000106	0.000124	CcSEcCtD
Varenicline—Ill-defined disorder—Doxorubicin—prostate cancer	0.000106	0.000124	CcSEcCtD
Varenicline—Pruritus—Docetaxel—prostate cancer	0.000105	0.000124	CcSEcCtD
Varenicline—Anaemia—Doxorubicin—prostate cancer	0.000105	0.000124	CcSEcCtD
Varenicline—Gastrointestinal pain—Prednisone—prostate cancer	0.000105	0.000123	CcSEcCtD
Varenicline—Arthralgia—Epirubicin—prostate cancer	0.000105	0.000123	CcSEcCtD
Varenicline—Chest pain—Epirubicin—prostate cancer	0.000105	0.000123	CcSEcCtD
Varenicline—Myalgia—Epirubicin—prostate cancer	0.000105	0.000123	CcSEcCtD
Varenicline—Agitation—Doxorubicin—prostate cancer	0.000105	0.000123	CcSEcCtD
Varenicline—Anxiety—Epirubicin—prostate cancer	0.000104	0.000123	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000104	0.000122	CcSEcCtD
Varenicline—Discomfort—Epirubicin—prostate cancer	0.000104	0.000122	CcSEcCtD
Varenicline—Asthenia—Capecitabine—prostate cancer	0.000103	0.000122	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6—prostate cancer	0.000103	0.000896	CbGpPWpGaD
Varenicline—Malaise—Doxorubicin—prostate cancer	0.000103	0.000121	CcSEcCtD
Varenicline—Dry mouth—Epirubicin—prostate cancer	0.000103	0.00012	CcSEcCtD
Varenicline—Vertigo—Doxorubicin—prostate cancer	0.000102	0.00012	CcSEcCtD
Varenicline—Syncope—Doxorubicin—prostate cancer	0.000102	0.00012	CcSEcCtD
Varenicline—Urticaria—Prednisone—prostate cancer	0.000102	0.00012	CcSEcCtD
Varenicline—Pruritus—Capecitabine—prostate cancer	0.000102	0.00012	CcSEcCtD
Varenicline—Diarrhoea—Docetaxel—prostate cancer	0.000102	0.00012	CcSEcCtD
Varenicline—Abdominal pain—Prednisone—prostate cancer	0.000102	0.000119	CcSEcCtD
Varenicline—Body temperature increased—Prednisone—prostate cancer	0.000102	0.000119	CcSEcCtD
Varenicline—Palpitations—Doxorubicin—prostate cancer	0.000101	0.000118	CcSEcCtD
Varenicline—Oedema—Epirubicin—prostate cancer	0.0001	0.000118	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—MDM2—prostate cancer	0.0001	0.000873	CbGpPWpGaD
Varenicline—Loss of consciousness—Doxorubicin—prostate cancer	0.0001	0.000118	CcSEcCtD
Varenicline—Infection—Epirubicin—prostate cancer	9.98e-05	0.000117	CcSEcCtD
Varenicline—Cough—Doxorubicin—prostate cancer	9.94e-05	0.000117	CcSEcCtD
Varenicline—Shock—Epirubicin—prostate cancer	9.89e-05	0.000116	CcSEcCtD
Varenicline—Convulsion—Doxorubicin—prostate cancer	9.87e-05	0.000116	CcSEcCtD
Varenicline—Diarrhoea—Capecitabine—prostate cancer	9.87e-05	0.000116	CcSEcCtD
Varenicline—Nervous system disorder—Epirubicin—prostate cancer	9.85e-05	0.000116	CcSEcCtD
Varenicline—Dizziness—Docetaxel—prostate cancer	9.85e-05	0.000116	CcSEcCtD
Varenicline—Thrombocytopenia—Epirubicin—prostate cancer	9.84e-05	0.000116	CcSEcCtD
Varenicline—Hypertension—Doxorubicin—prostate cancer	9.84e-05	0.000116	CcSEcCtD
Varenicline—Tachycardia—Epirubicin—prostate cancer	9.81e-05	0.000115	CcSEcCtD
Varenicline—Skin disorder—Epirubicin—prostate cancer	9.76e-05	0.000115	CcSEcCtD
Varenicline—Hyperhidrosis—Epirubicin—prostate cancer	9.71e-05	0.000114	CcSEcCtD
Varenicline—Chest pain—Doxorubicin—prostate cancer	9.7e-05	0.000114	CcSEcCtD
Varenicline—Myalgia—Doxorubicin—prostate cancer	9.7e-05	0.000114	CcSEcCtD
Varenicline—Arthralgia—Doxorubicin—prostate cancer	9.7e-05	0.000114	CcSEcCtD
Varenicline—Anxiety—Doxorubicin—prostate cancer	9.66e-05	0.000114	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	9.63e-05	0.000113	CcSEcCtD
Varenicline—Discomfort—Doxorubicin—prostate cancer	9.58e-05	0.000113	CcSEcCtD
Varenicline—Anorexia—Epirubicin—prostate cancer	9.58e-05	0.000113	CcSEcCtD
Varenicline—Dizziness—Capecitabine—prostate cancer	9.54e-05	0.000112	CcSEcCtD
Varenicline—Dry mouth—Doxorubicin—prostate cancer	9.48e-05	0.000111	CcSEcCtD
Varenicline—Vomiting—Docetaxel—prostate cancer	9.47e-05	0.000111	CcSEcCtD
Varenicline—Hypersensitivity—Prednisone—prostate cancer	9.47e-05	0.000111	CcSEcCtD
Varenicline—Rash—Docetaxel—prostate cancer	9.39e-05	0.00011	CcSEcCtD
Varenicline—Hypotension—Epirubicin—prostate cancer	9.39e-05	0.00011	CcSEcCtD
Varenicline—Dermatitis—Docetaxel—prostate cancer	9.38e-05	0.00011	CcSEcCtD
Varenicline—Headache—Docetaxel—prostate cancer	9.33e-05	0.00011	CcSEcCtD
Varenicline—Oedema—Doxorubicin—prostate cancer	9.3e-05	0.000109	CcSEcCtD
Varenicline—Infection—Doxorubicin—prostate cancer	9.24e-05	0.000109	CcSEcCtD
Varenicline—Asthenia—Prednisone—prostate cancer	9.22e-05	0.000108	CcSEcCtD
Varenicline—Vomiting—Capecitabine—prostate cancer	9.17e-05	0.000108	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.15e-05	0.000108	CcSEcCtD
Varenicline—Shock—Doxorubicin—prostate cancer	9.15e-05	0.000107	CcSEcCtD
Varenicline—Nervous system disorder—Doxorubicin—prostate cancer	9.12e-05	0.000107	CcSEcCtD
Varenicline—Thrombocytopenia—Doxorubicin—prostate cancer	9.1e-05	0.000107	CcSEcCtD
Varenicline—Rash—Capecitabine—prostate cancer	9.09e-05	0.000107	CcSEcCtD
Varenicline—Pruritus—Prednisone—prostate cancer	9.09e-05	0.000107	CcSEcCtD
Varenicline—Insomnia—Epirubicin—prostate cancer	9.09e-05	0.000107	CcSEcCtD
Varenicline—Dermatitis—Capecitabine—prostate cancer	9.09e-05	0.000107	CcSEcCtD
Varenicline—Tachycardia—Doxorubicin—prostate cancer	9.07e-05	0.000107	CcSEcCtD
Varenicline—Headache—Capecitabine—prostate cancer	9.04e-05	0.000106	CcSEcCtD
Varenicline—Skin disorder—Doxorubicin—prostate cancer	9.03e-05	0.000106	CcSEcCtD
Varenicline—Hyperhidrosis—Doxorubicin—prostate cancer	8.99e-05	0.000106	CcSEcCtD
Varenicline—Dyspnoea—Epirubicin—prostate cancer	8.96e-05	0.000105	CcSEcCtD
Varenicline—Somnolence—Epirubicin—prostate cancer	8.93e-05	0.000105	CcSEcCtD
Varenicline—Anorexia—Doxorubicin—prostate cancer	8.86e-05	0.000104	CcSEcCtD
Varenicline—Nausea—Docetaxel—prostate cancer	8.85e-05	0.000104	CcSEcCtD
Varenicline—Dyspepsia—Epirubicin—prostate cancer	8.84e-05	0.000104	CcSEcCtD
Varenicline—Diarrhoea—Prednisone—prostate cancer	8.79e-05	0.000103	CcSEcCtD
Varenicline—Decreased appetite—Epirubicin—prostate cancer	8.73e-05	0.000103	CcSEcCtD
Varenicline—Hypotension—Doxorubicin—prostate cancer	8.69e-05	0.000102	CcSEcCtD
Varenicline—Gastrointestinal disorder—Epirubicin—prostate cancer	8.67e-05	0.000102	CcSEcCtD
Varenicline—Fatigue—Epirubicin—prostate cancer	8.66e-05	0.000102	CcSEcCtD
Varenicline—Constipation—Epirubicin—prostate cancer	8.59e-05	0.000101	CcSEcCtD
Varenicline—Pain—Epirubicin—prostate cancer	8.59e-05	0.000101	CcSEcCtD
Varenicline—Nausea—Capecitabine—prostate cancer	8.57e-05	0.000101	CcSEcCtD
Varenicline—Dizziness—Prednisone—prostate cancer	8.5e-05	9.98e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.47e-05	9.95e-05	CcSEcCtD
Varenicline—Insomnia—Doxorubicin—prostate cancer	8.41e-05	9.88e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6—prostate cancer	8.39e-05	0.00073	CbGpPWpGaD
Varenicline—Dyspnoea—Doxorubicin—prostate cancer	8.29e-05	9.74e-05	CcSEcCtD
Varenicline—Feeling abnormal—Epirubicin—prostate cancer	8.28e-05	9.73e-05	CcSEcCtD
Varenicline—Somnolence—Doxorubicin—prostate cancer	8.27e-05	9.71e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Epirubicin—prostate cancer	8.22e-05	9.65e-05	CcSEcCtD
Varenicline—Dyspepsia—Doxorubicin—prostate cancer	8.18e-05	9.62e-05	CcSEcCtD
Varenicline—Vomiting—Prednisone—prostate cancer	8.17e-05	9.6e-05	CcSEcCtD
Varenicline—Rash—Prednisone—prostate cancer	8.1e-05	9.52e-05	CcSEcCtD
Varenicline—Dermatitis—Prednisone—prostate cancer	8.09e-05	9.51e-05	CcSEcCtD
Varenicline—Decreased appetite—Doxorubicin—prostate cancer	8.08e-05	9.5e-05	CcSEcCtD
Varenicline—Headache—Prednisone—prostate cancer	8.05e-05	9.46e-05	CcSEcCtD
Varenicline—Gastrointestinal disorder—Doxorubicin—prostate cancer	8.03e-05	9.43e-05	CcSEcCtD
Varenicline—Fatigue—Doxorubicin—prostate cancer	8.02e-05	9.42e-05	CcSEcCtD
Varenicline—Urticaria—Epirubicin—prostate cancer	7.98e-05	9.38e-05	CcSEcCtD
Varenicline—Pain—Doxorubicin—prostate cancer	7.95e-05	9.34e-05	CcSEcCtD
Varenicline—Constipation—Doxorubicin—prostate cancer	7.95e-05	9.34e-05	CcSEcCtD
Varenicline—Body temperature increased—Epirubicin—prostate cancer	7.94e-05	9.33e-05	CcSEcCtD
Varenicline—Abdominal pain—Epirubicin—prostate cancer	7.94e-05	9.33e-05	CcSEcCtD
Varenicline—Feeling abnormal—Doxorubicin—prostate cancer	7.66e-05	9e-05	CcSEcCtD
Varenicline—Nausea—Prednisone—prostate cancer	7.63e-05	8.97e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Doxorubicin—prostate cancer	7.6e-05	8.93e-05	CcSEcCtD
Varenicline—Hypersensitivity—Epirubicin—prostate cancer	7.4e-05	8.7e-05	CcSEcCtD
Varenicline—Urticaria—Doxorubicin—prostate cancer	7.39e-05	8.68e-05	CcSEcCtD
Varenicline—Abdominal pain—Doxorubicin—prostate cancer	7.35e-05	8.64e-05	CcSEcCtD
Varenicline—Body temperature increased—Doxorubicin—prostate cancer	7.35e-05	8.64e-05	CcSEcCtD
Varenicline—Asthenia—Epirubicin—prostate cancer	7.21e-05	8.47e-05	CcSEcCtD
Varenicline—Pruritus—Epirubicin—prostate cancer	7.11e-05	8.35e-05	CcSEcCtD
Varenicline—Diarrhoea—Epirubicin—prostate cancer	6.87e-05	8.08e-05	CcSEcCtD
Varenicline—Hypersensitivity—Doxorubicin—prostate cancer	6.85e-05	8.05e-05	CcSEcCtD
Varenicline—Asthenia—Doxorubicin—prostate cancer	6.67e-05	7.84e-05	CcSEcCtD
Varenicline—Dizziness—Epirubicin—prostate cancer	6.64e-05	7.81e-05	CcSEcCtD
Varenicline—Pruritus—Doxorubicin—prostate cancer	6.58e-05	7.73e-05	CcSEcCtD
Varenicline—Vomiting—Epirubicin—prostate cancer	6.39e-05	7.51e-05	CcSEcCtD
Varenicline—Diarrhoea—Doxorubicin—prostate cancer	6.36e-05	7.47e-05	CcSEcCtD
Varenicline—Rash—Epirubicin—prostate cancer	6.34e-05	7.44e-05	CcSEcCtD
Varenicline—Dermatitis—Epirubicin—prostate cancer	6.33e-05	7.44e-05	CcSEcCtD
Varenicline—Headache—Epirubicin—prostate cancer	6.29e-05	7.4e-05	CcSEcCtD
Varenicline—Dizziness—Doxorubicin—prostate cancer	6.15e-05	7.22e-05	CcSEcCtD
Varenicline—Nausea—Epirubicin—prostate cancer	5.97e-05	7.01e-05	CcSEcCtD
Varenicline—Vomiting—Doxorubicin—prostate cancer	5.91e-05	6.95e-05	CcSEcCtD
Varenicline—Rash—Doxorubicin—prostate cancer	5.86e-05	6.89e-05	CcSEcCtD
Varenicline—Dermatitis—Doxorubicin—prostate cancer	5.86e-05	6.88e-05	CcSEcCtD
Varenicline—Headache—Doxorubicin—prostate cancer	5.82e-05	6.84e-05	CcSEcCtD
Varenicline—Nausea—Doxorubicin—prostate cancer	5.52e-05	6.49e-05	CcSEcCtD
